238 related articles for article (PubMed ID: 30353265)
21. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models.
Chonan M; Saito R; Shoji T; Shibahara I; Kanamori M; Sonoda Y; Watanabe M; Kikuchi T; Ishii N; Tominaga T
Neuro Oncol; 2015 Nov; 17(11):1453-62. PubMed ID: 26008605
[TBL] [Abstract][Full Text] [Related]
22. ATP binding cassette (ABC) transporters: expression and clinical value in glioblastoma.
Dréan A; Rosenberg S; Lejeune FX; Goli L; Nadaradjane AA; Guehennec J; Schmitt C; Verreault M; Bielle F; Mokhtari K; Sanson M; Carpentier A; Delattre JY; Idbaih A
J Neurooncol; 2018 Jul; 138(3):479-486. PubMed ID: 29520610
[TBL] [Abstract][Full Text] [Related]
23. IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors.
Joalland N; Chauvin C; Oliver L; Vallette FM; Pecqueur C; Jarry U; Scotet E
J Immunother; 2018 Jun; 41(5):224-231. PubMed ID: 29683891
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma.
Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC
PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882
[TBL] [Abstract][Full Text] [Related]
25. Immune Microenvironment in Glioblastoma Subtypes.
Chen Z; Hambardzumyan D
Front Immunol; 2018; 9():1004. PubMed ID: 29867979
[TBL] [Abstract][Full Text] [Related]
26. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment.
Jia D; Li S; Li D; Xue H; Yang D; Liu Y
Aging (Albany NY); 2018 Apr; 10(4):592-605. PubMed ID: 29676997
[TBL] [Abstract][Full Text] [Related]
27. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value and immune cell infiltration of hypoxic phenotype-related gene signatures in glioblastoma microenvironment.
Xiao K; Tan J; Yuan J; Peng G; Long W; Su J; Xiao Y; Xiao Q; Wu C; Qin C; Hu L; Liu K; Liu S; Zhou H; Ning Y; Ding X; Liu Q
J Cell Mol Med; 2020 Nov; 24(22):13235-13247. PubMed ID: 33009892
[TBL] [Abstract][Full Text] [Related]
29. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
30. OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.
Shibahara I; Saito R; Zhang R; Chonan M; Shoji T; Kanamori M; Sonoda Y; Kumabe T; Kanehira M; Kikuchi T; So T; Watanabe T; Takahashi H; Iwabuchi E; Tanaka Y; Shibahara Y; Sasano H; Ishii N; Tominaga T
Mol Cancer; 2015 Feb; 14():41. PubMed ID: 25744203
[TBL] [Abstract][Full Text] [Related]
31. Immune landscapes associated with different glioblastoma molecular subtypes.
Martinez-Lage M; Lynch TM; Bi Y; Cocito C; Way GP; Pal S; Haller J; Yan RE; Ziober A; Nguyen A; Kandpal M; O'Rourke DM; Greenfield JP; Greene CS; Davuluri RV; Dahmane N
Acta Neuropathol Commun; 2019 Nov; 7(1):203. PubMed ID: 31815646
[TBL] [Abstract][Full Text] [Related]
32. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
33. The Safety of available immunotherapy for the treatment of glioblastoma.
Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
[TBL] [Abstract][Full Text] [Related]
34. T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints.
Mirzaei R; Sarkar S; Yong VW
Trends Immunol; 2017 Feb; 38(2):104-115. PubMed ID: 27964820
[TBL] [Abstract][Full Text] [Related]
35. Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.
Khalsa JK; Shah K
Cells; 2021 Feb; 10(3):. PubMed ID: 33668856
[TBL] [Abstract][Full Text] [Related]
36. Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A; Heilinger T; Lavelle EC; Prehn JH
J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
[TBL] [Abstract][Full Text] [Related]
37. Characterization of ferroptosis signature to evaluate the predict prognosis and immunotherapy in glioblastoma.
Zhu X; Zhou Y; Ou Y; Cheng Z; Han D; Chu Z; Pan S
Aging (Albany NY); 2021 Jul; 13(13):17655-17672. PubMed ID: 34244461
[TBL] [Abstract][Full Text] [Related]
38. Immune Cytolytic Activity and Strategies for Therapeutic Treatment.
Agioti S; Zaravinos A
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612436
[TBL] [Abstract][Full Text] [Related]
39. Transcriptome and single-cell analysis reveal the contribution of immunosuppressive microenvironment for promoting glioblastoma progression.
Ni L; Sun P; Zhang S; Qian B; Chen X; Xiong M; Li B
Front Immunol; 2022; 13():1051701. PubMed ID: 36685556
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]